Actoxumab is a human monoclonal antibody that binds to C. difficile toxin A and thus preventing toxin from binding to host cells. Actoxumab was developed in conjunction with bezlotoxumab for the treatment of Clostridioides difficile infection.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.